Long-term suppressive effect of octreotide on progression of metastatic gastrinoma with multiple endocrine neoplasia type 1: seven-year follow up.
A 30-year-old woman had a history of prolactinoma and primary hyperparathyroidism. She was diagnosed as having multiple endocrine neoplasia type 1 with gastrinoma and liver metastases. Octreotide therapy was started and the serum gastrin level decreased immediately. Octreotide continued to suppress gastrin secretion over the next 7 years. The Ki67/MIB1 proliferation index of this tumor was only 0.5 % and somatostatin receptor (SSTR) 2 expression was very strong in both 2002 and 2009. This case suggests the importance of investigating the Ki67/MIB1 index and SSTR expression in patients with metastatic gastrinoma.
Yamaguchi
Megu
M
Department of Endocrinology and Metabolism, Sumitomo Hospital, Osaka. megmegoo_y@yahoo.co.jp
Yamada
Yuya
Y
Hosokawa
Yoshiya
Y
Iwamoto
Ryuya
R
Tamba
Sachiko
S
Ihara
Arisa
A
Yamamoto
Koji
K
Hoshida
Yoshihiko
Y
Matsuzawa
Yuji
Y
D000328:Adult; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D015408:Gastrinoma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D018761:Multiple Endocrine Neoplasia Type 1 / Q000175:diagnosis / Q000188:drug therapy*; D015282:Octreotide / Q000008:administration & dosage*; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors
D015282:Octreotide